(NASDAQ: IMNM) Immunome's forecast annual revenue growth rate of 71.01% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.41%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.75%.
Immunome's revenue in 2025 is $12,589,000.On average, 4 Wall Street analysts forecast IMNM's revenue for 2025 to be $604,527,581, with the lowest IMNM revenue forecast at $600,610,555, and the highest IMNM revenue forecast at $609,315,056. On average, 3 Wall Street analysts forecast IMNM's revenue for 2026 to be $1,027,392,229, with the lowest IMNM revenue forecast at $202,814,869, and the highest IMNM revenue forecast at $2,315,397,213.
In 2027, IMNM is forecast to generate $6,116,217,487 in revenue, with the lowest revenue forecast at $4,352,250,400 and the highest revenue forecast at $7,686,074,206.